Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE combined with camrelizumab and apatinib for unresectable advanced hepatocellular carcinoma
ChiCTR2200065643Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Progression-free survival. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200065643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065643.